The Pennsylvania Department of Health (PADOH) released a health advisory on Thursday, August 1, 2024. Below is a summary.
- Medetomidine, a veterinary alpha-2 agonist that is more potent than xylazine, has been
detected in the drug supply in Philadelphia. This was followed by detection in Pittsburgh. - Medetomidine is not approved for use in humans.
- Medetomidine overdose in humans can cause extreme sleepiness, very low blood pressure,
slow heart rate, trouble breathing and even coma or death. - Healthcare providers should be aware of the increased prevalence of medetomidine and
other adulterants in the volatile drug supply and be prepared to deploy harm reduction
practices such as disseminating harm reduction supplies, conducting overdose response,
and caring for xylazine-associated wounds. - Use naloxone to respond to any suspected overdose.
- If you have any questions, please call DOH at 1-877-PA-HEALTH (1-877-724-3258) or your
local health department. - For consultation related to potential exposures and/or overdoses, please contact the Poison
Control Center at 1-800-222-1222.
